A  A  A   Print
FDA-Approved Drugs

FDA-Approved Drugs

The following drugs have been approved since the year 2000 for the treatment of prostate cancer:

Jevtana (cabazitaxel)

FDA approved June 2010

This chemotherapy drug is approved for use in combination with prednisone (a steroid) in patients with hormone-refractory, metastatic prostate cancer who have already been treated with docetaxel.

This drug seems to work in a way similar to docetaxel (inhibiting microtubules, which cancer cells need to divide), but it works in some men whose cancer is no longer responding to docetaxel.

Provenge (sipuleucel-T)

FDA approved May 2010

This drug is a type of autologous cellular immune therapy approved for the treatment of metastatic, hormone-refractory prostate cancer that is causing few or no symptoms.

This new type of treatment is sometimes referred to as a prostate cancer vaccine. For this treatment, special immune cells are removed from a man's blood and sent to a lab, where they are treated to make them more likely to attack prostate cancer cells. A few days later they are put back into the blood (similar to a blood transfusion). It is given in three doses, with about two weeks between doses.

Firmagon (degarelix)

FDA approved December 2008

This drug, an LHRH antagonist, is approved for the palliative treatment of advanced prostate cancer.

Vantas (histrelin acetate)

FDA approved October 2004

This drug, an LHRH agonist, is approved for the palliative treatment of advanced prostate cancer.

Taxotere (docetaxel)

FDA approved May 2004

Injecting this chemotherapy drug in combination with prednisone (a steroid), is approved for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

Taxotere works by inhibiting tubulin, a protein essential to cell division, thus preventing cancer cells from dividing and growing in number.

Plenaxis depot (abarelix)

FDA approved November 2003

This drug, an LHRH antagonist, was approved for the palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following: (1) risk of neurological compromise due to metastases, (2) ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or (3) severe bone pain from skeletal metastases persisting on narcotic analgesia.

This drug is no longer available in the United States.

Zometa (zoledronic acid)

FDA approved February 2002

This drug, a bisphosphonate, is approved for the palliative treatment of prostate cancer that has spread to the bones and that has progressed after at least one type of hormone therapy.

Eligard (leuprolide acetate)

FDA approved  January 2002

This drug, an LHRH agonist, is approved for the palliative treatment of advanced prostate cancer. 

Trelstar (triptorelin)

FDA approved June 2000

This drug, an LHRH agonist, is approved for the palliative treatment of advanced prostate cancer.

 
Today's Interactive Tools
Related Items

The third-party content provided in the Health Library of phoebeputney.com is for informational purposes only and is not designed to diagnose or treat a health problem or disease, or replace the professional medical advice you receive from your physician. If you or your child has or suspect you may have a health problem, please consult your primary care physician. If you or your child may have a medical emergency, call your doctor or 911 or other emergency health care provider immediately in the United States or the appropriate health agency of your country. For more information regarding site usage, please visit: Privacy Information, Terms of Use or Disclaimer.

Follow us online:

© 2014 Phoebe Putney Health System  |  417 Third Avenue, Albany, Georgia 31701  |  Telephone 877.312.1167

Phoebe Putney Health System is a network of hospitals, family medicine clinics, rehab facilities, auxiliary services, and medical education training facilities. Founded in 1911,
Phoebe Putney Memorial Hospital (the flagship hospital) is one of Georgia's largest comprehensive regional medical centers. From the beginning, Phoebe's mission and vision
has been to bring the finest medical talent and technology to the citizens of Southwest Georgia, and to serve all citizens of the community regardless of ability to pay.